GPCR Quote, Financials, Valuation and Earnings

Pfizer has a net margin of -- compared to Structure Therapeutics's net margin of 25.23%. Structure Therapeutics's return on equity of -- beat Pfizer's return on equity of 4.63%.

Structure Therapeutics has a consensus price target of $85.75, signalling upside risk potential of 203.54%. On the other hand Pfizer has an analysts' consensus of $31.86 which suggests that it could grow by 19.16%. Given that Structure Therapeutics has higher upside potential than Pfizer, analysts believe Structure Therapeutics is more attractive than Pfizer.

Structure Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pfizer has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.739%.

Structure Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.28% to investors and pays a quarterly dividend of $0.42 per share. Structure Therapeutics pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.

Structure Therapeutics quarterly revenues are --, which are smaller than Pfizer quarterly revenues of $17.7B. Structure Therapeutics's net income of -$34M is lower than Pfizer's net income of $4.5B. Notably, Structure Therapeutics's price-to-earnings ratio is -- while Pfizer's PE ratio is 36.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Structure Therapeutics is -- versus 2.56x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -- compared to Structure Therapeutics's net margin of 36.03%. Structure Therapeutics's return on equity of -- beat Regeneron Pharmaceuticals's return on equity of 17.19%.

Structure Therapeutics has a consensus price target of $85.75, signalling upside risk potential of 203.54%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $1,053.08 which suggests that it could grow by 47.39%. Given that Structure Therapeutics has higher upside potential than Regeneron Pharmaceuticals, analysts believe Structure Therapeutics is more attractive than Regeneron Pharmaceuticals.

Structure Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.084, suggesting its less volatile than the S&P 500 by 91.622%.

Structure Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Structure Therapeutics pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Structure Therapeutics quarterly revenues are --, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.7B. Structure Therapeutics's net income of -$34M is lower than Regeneron Pharmaceuticals's net income of $1.3B. Notably, Structure Therapeutics's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 17.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Structure Therapeutics is -- versus 5.94x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Skye Bioscience has a net margin of -- compared to Structure Therapeutics's net margin of --. Structure Therapeutics's return on equity of -- beat Skye Bioscience's return on equity of --.

Structure Therapeutics has a consensus price target of $85.75, signalling upside risk potential of 203.54%. On the other hand Skye Bioscience has an analysts' consensus of -- which suggests that it could grow by 605.88%. Given that Skye Bioscience has higher upside potential than Structure Therapeutics, analysts believe Skye Bioscience is more attractive than Structure Therapeutics.

Structure Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Skye Bioscience has a beta of 1.719, suggesting its more volatile than the S&P 500 by 71.874%.

Structure Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Skye Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Structure Therapeutics pays -- of its earnings as a dividend. Skye Bioscience pays out -- of its earnings as a dividend.

Structure Therapeutics quarterly revenues are --, which are smaller than Skye Bioscience quarterly revenues of --. Structure Therapeutics's net income of -$34M is lower than Skye Bioscience's net income of -$3.9M. Notably, Structure Therapeutics's price-to-earnings ratio is -- while Skye Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Structure Therapeutics is -- versus 258.86x for Skye Bioscience. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of -- compared to Structure Therapeutics's net margin of --. Structure Therapeutics's return on equity of -- beat Viking Therapeutics's return on equity of --.

Structure Therapeutics has a consensus price target of $85.75, signalling upside risk potential of 203.54%. On the other hand Viking Therapeutics has an analysts' consensus of $110.00 which suggests that it could grow by 159.74%. Given that Structure Therapeutics has higher upside potential than Viking Therapeutics, analysts believe Structure Therapeutics is more attractive than Viking Therapeutics.

Structure Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.884, suggesting its less volatile than the S&P 500 by 11.566%.

Structure Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Structure Therapeutics pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

Structure Therapeutics quarterly revenues are --, which are smaller than Viking Therapeutics quarterly revenues of --. Structure Therapeutics's net income of -$34M is lower than Viking Therapeutics's net income of -$24.9M. Notably, Structure Therapeutics's price-to-earnings ratio is -- while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Structure Therapeutics is -- versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.